DE602005026432D1 - Leptin antagonisten - Google Patents

Leptin antagonisten

Info

Publication number
DE602005026432D1
DE602005026432D1 DE602005026432T DE602005026432T DE602005026432D1 DE 602005026432 D1 DE602005026432 D1 DE 602005026432D1 DE 602005026432 T DE602005026432 T DE 602005026432T DE 602005026432 T DE602005026432 T DE 602005026432T DE 602005026432 D1 DE602005026432 D1 DE 602005026432D1
Authority
DE
Germany
Prior art keywords
leptin
leptin antagonists
antagonists
amino acid
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005026432T
Other languages
German (de)
English (en)
Inventor
Arieh Gertler
Isabelle Callebaut
Jean Djiane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie
Institut National de la Recherche Agronomique INRA
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Universite Pierre et Marie Curie
Institut National de la Recherche Agronomique INRA
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie, Institut National de la Recherche Agronomique INRA, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Universite Pierre et Marie Curie
Publication of DE602005026432D1 publication Critical patent/DE602005026432D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602005026432T 2004-11-26 2005-11-24 Leptin antagonisten Expired - Lifetime DE602005026432D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/996,607 US7307142B2 (en) 2004-11-26 2004-11-26 Leptin antagonists
PCT/IL2005/001250 WO2006056987A2 (en) 2004-11-26 2005-11-24 Leptin antagonists

Publications (1)

Publication Number Publication Date
DE602005026432D1 true DE602005026432D1 (de) 2011-03-31

Family

ID=36204374

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026432T Expired - Lifetime DE602005026432D1 (de) 2004-11-26 2005-11-24 Leptin antagonisten

Country Status (8)

Country Link
US (1) US7307142B2 (https=)
EP (1) EP1814986B1 (https=)
JP (1) JP5113526B2 (https=)
CN (1) CN101189335B (https=)
AT (1) ATE498683T1 (https=)
DE (1) DE602005026432D1 (https=)
ES (1) ES2363011T3 (https=)
WO (1) WO2006056987A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
AU2011243965A1 (en) 2010-04-22 2012-12-06 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center High affinity leptins and leptin antagonists
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
IT1423968B1 (https=) * 2014-04-28 2016-08-26
EP3261582B1 (en) * 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
LT3538554T (lt) * 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
KR20210104744A (ko) 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
WO2024050285A2 (en) * 2022-08-31 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Leptin analogs for treating obesity and weight management

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US20020160935A1 (en) * 2000-03-24 2002-10-31 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
WO1998012224A1 (en) * 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
CN1491232A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰肥胖蛋白

Also Published As

Publication number Publication date
JP5113526B2 (ja) 2013-01-09
US20060154859A1 (en) 2006-07-13
CN101189335A (zh) 2008-05-28
WO2006056987A2 (en) 2006-06-01
CN101189335B (zh) 2012-01-11
US7307142B2 (en) 2007-12-11
ES2363011T3 (es) 2011-07-18
JP2008521795A (ja) 2008-06-26
EP1814986A2 (en) 2007-08-08
WO2006056987A3 (en) 2006-08-24
ATE498683T1 (de) 2011-03-15
EP1814986B1 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
ATE498683T1 (de) Leptin antagonisten
SA519410284B1 (ar) Cd3 بنيات بولي ببتيد متعددة النوعية ذات ربط ل مقيد وطرق لاستخدامها
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
TW200745163A (en) Peptides that block the binding of IgG to FcRn
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
DK2035447T3 (da) Polypeptid
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
LU91989I2 (fr) Bydureon
ATE428727T1 (de) Neue, an den erythropoietinrezeptor bindende peptide
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
SG170750A1 (en) Stabilized polypeptide compositions
SMP200800060B (it) Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
EA201100072A1 (ru) Новые композиции и способы
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
MA56397A (fr) Protéines de liaison à l'il1rap
ATE404225T1 (de) Radiofluorierte peptide
EA201100071A1 (ru) Новые композиции и способы
DK1737961T3 (da) Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
EP2362877A4 (en) POLYNUCLEOTIDES CODING FOR HUMAN TRIM-CYP FUSION POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
MX2008000230A (es) Proteinas de enlace il-6.
DE602005022457D1 (de) Neublastin-varianten
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
EP1878745A4 (en) HUMANINE RECEPTOR OR RECEPTOR FOR A HUMAN INDEPENDENT POLYPEPTIDE